e-Device

DEVICE2 trials

Sponsors

UCB BIOSCIENCES, Inc., UCB Biopharma S.P.R.L.

Conditions

Active Ankylosing SpondylitisActive Psoriatic ArthritisHealthyModerate and Severe Active Rheumatoid ArthritisModerately to Severely Active Crohn's Disease

Phase 1

Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

CompletedNCT02806219

UCB BIOSCIENCES, Inc.Healthy

Start: 2016-03-31End: 2016-11-30Updated: 2016-11-17

Phase 3

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

CompletedNCT03357471

UCB Biopharma S.P.R.L.Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis +1

Start: 2017-11-03End: 2018-07-02Updated: 2019-10-25

Related Papers

Development and psychometric evaluation of the assessment of self-injection questionnaire: an adaptation of the self-injection assessment questionnaire

Health and Quality of Life Outcomes2020-11-047 citations

A multicenter, open-label study to evaluate the safe and effective use of a new electromechanical auto-injection device for self-injection of certolizumab pegol.

2020-04-246 citations